Compare Raymond James Financial, Inc. (RJF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Sanofi SA — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 3.2× Raymond James Financial, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| RJF | SNY | |
|---|---|---|
Market Cap | $32.73B | $104.85B |
Sector | Financials | Health |
52-Week High | $176.43 | $52.34 |
52-Week Low | $140.89 | $41.33 |
Dividend Yield | 1.29% | 5.53% |
Enterprise Value | — | $121.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $167.93, down 0.26% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong fundamental performance with 2025 revenue of $13.84B and net income of $2.14B, supported by a P/E of 15.89. Analyst consensus is positive with a $176.83 price target, and recent news highlights advisor recruitment driving growth.
The outlook for RJF remains favorable due to earnings momentum and institutional interest, though risks include expense pressures and market volatility. The stock presents a growth opportunity with solid valuation support, but investors should monitor cost management and macroeconomic factors that could impact financial services performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
